Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Go back to Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.58 -0.03 (4.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.61 | 52 Week High | $9.58 | |||
| Open | $0.61 | 52 Week Low | $2.34 | |||
| Day High | $0.61 | P/E | N/A | |||
| Day Low | $0.57 | EPS | $-0.34 | |||
| Volume | 522,834 | |||||
